ReviewCardiovascular diabetology2023
The cardio-renal-metabolic connection: a review of the evidence.
Review in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07569744 (Effectiveness of Resveratrol Addition in Improving Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes Mellitus Patients), which is not on this map. Cited by 232 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Resveratrol Addition in Improving Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial
Who cites it
232 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mortality and cardiovascular risk of triglyceride-glucose and derived indices in cardiovascular-kidney-metabolic syndrome stages 0-3: a dose-response meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.Diabetes, obesity & metabolism · 2026Trial
- APOSCREEN-1 - a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein.BMC nephrology · 2026Trial
- Intensive Blood Pressure Control and Cardiovascular Outcomes Across Cardiovascular-Kidney-Metabolic Syndrome Stages: A Post Hoc Analysis of the China Rural Hypertension Control Project.JAMA network open · 2026Trial
- High prevalence and mortality risk of nocturia in cardiovascular-kidney-metabolic syndrome: a national cohort study and clinical validation.Clinical and experimental nephrology · 2026Article
- Article
- Macroalbuminuria as a marker of cardiac damage in patients with type 2 diabetes: insights from multimodality cardiac imaging and biomarkers.Journal of physiology and biochemistry · 2026Article
- Integrated Cardio-Renal-Metabolic Risk Profiling in Patients with Type 2 Diabetes: A Machine Learning-Assisted Cross-Sectional Analysis.Journal of clinical medicine · 2026Article
- Body composition phenotypes are key predictors of cardiovascular-kidney-metabolic multimorbidity and long-term mortality: insights from a population-based cohort study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Mortality trends involving chronic kidney disease and electrolyte and acid-base disorders in the United States, 1999-2023: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Article
- Association Between Naples Prognostic Score and All-Cause Mortality in Individuals with Cardio-Renal-Metabolic Multimorbidity: A Cohort Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Effectiveness of plasma atherogenic index as a predictor of cardiovascular risk in patients with metabolic syndrome and related cardiometabolic conditions: a systematic review.Cardiovascular endocrinology & metabolism · 2026Review
- Association between body roundness index and progression of cardio-renal-metabolic diseases using multistate models.GeroScience · 2026Article
- Association of cardiovascular-kidney-metabolic syndrome with blinding eye diseases: insights from a UK Biobank cohort analysis.Eye (London, England) · 2026Article
- Incident chronic kidney disease risk and the predictive value of the uric acid-to-HDL ratio in lean and non-lean MASLD: a prospective cohort and multi-omics study.International urology and nephrology · 2026Article
- Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase-Aldosterone and Ghrelin-Leptin Axes.Biomolecules · 2026Review
- Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF-κB and NLRP3 Signaling Pathways.Journal of biochemical and molecular toxicology · 2026Article
- An Integrated Therapeutic Strategy for Cardiorenal Syndrome to Target Oxidative Stress, Inflammation, and Fibrosis.Reviews in cardiovascular medicine · 2026Review
- Article
- Inflammatory and Metabolic Biomarkers Associated with In-Hospital Mortality in Patients Hospitalized with Heart Failure.Metabolites · 2026Article
172 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD), are recognized among the most disruptive public health issues of the current century. A large body of evidence from epidemiological and clinical research supports the existence of a strong interconnection between these conditions, such that the unifying term cardio-metabolic-renal (CMR) disease has been defined. This coexistence has remarkable epidemiological, pathophysiologic, and prognostic implications. The mechanisms of hyperglycemia-induced damage to the cardio-renal system are well validated, as are those that tie cardiac and renal disease together. Yet, it remains controversial how and to what extent CVD and CKD can promote metabolic dysregulation. The aim of this review is to recapitulate the epidemiology of the CMR connections; to discuss the well-established, as well as the putative and emerging mechanisms implicated in the interplay among these three entities; and to provide a pathophysiological background for an integrated therapeutic intervention aiming at interrupting this vicious crosstalks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.